ライフサイエンスコーパス: drug delivery vehicle

1 he bottom graphene layer upward to mimic the drug delivery vehicle.

2 H as the trigger, making dendrimers a unique drug delivery vehicle.

3 ing phage are potential imaging tools and/or drug delivery vehicles.

4 es of nanowires and photonic systems, and as drug delivery vehicles.

5 implications in evaluating the stability of drug delivery vehicles.

6 s have been developed and used clinically as drug delivery vehicles.

7 a new mechanism for the design of controlled drug delivery vehicles.

8 as the development of novel therapeutics and drug-delivery vehicles.

9 photoacoustic imaging and as light-activated drug-delivery vehicles.

10 plications: (1) metal-containing polymers as drug delivery vehicles; (2) metal-containing polymeric d

11 study mark the establishment of an amenable drug delivery vehicle and highlight the advantages of a

12 Despite its wide use as a drug delivery vehicle and the recent approval of a clini

13 Nanoparticle-based materials, such as drug delivery vehicles and diagnostic probes, currently

14 r biomedical applications as optical labels, drug-delivery vehicles and contrast agents in vivo.

15 uses including as anti-cancer agents, ocular drug delivery vehicles, and protein trafficking modulato

16 drug discovery, continuous manufacturing of drug delivery vehicles, and ultra-precise dosing of high

17 Drug delivery vehicles are often assessed for their abil

18 s, peptides, proteins, tissue scaffolds, and drug delivery vehicles, are conjugated to poly(ethylene

19 rticles have great potential as controllable drug delivery vehicles because of their size and modular

20 l structures with high potential as advanced drug delivery vehicles, bioreactors and artificial cells

21 bicide formulations can function not only as drug delivery vehicles, but also as physical barriers to

22 ults suggest that IF7 serves as an efficient drug delivery vehicle by targeting Anxa1 expressed on th

23 Nanoscale drug delivery vehicles can facilitate multimodal therapi

24 The therapeutic efficacy of systemic drug-delivery vehicles depends on their ability to evade

25 been part-modified with a polyoxazoline as a drug delivery vehicle for improving the therapeutic inde

26 roxyl PAMAM dendrimers could be an effective drug delivery vehicle for targeting fetal inflammation a

27 Here, we designed and tested a novel nanogel drug delivery vehicle for the immunosuppressant mycophen

28 Liposomes have been evaluated as drug delivery vehicles for decades, but their clinical s

29 -organized nanomicelles are highly efficient drug delivery vehicles for hydrophobic and partially hyd

30 articles (HNPs) have shown huge potential as drug delivery vehicles for pancreatic cancer.

31 vestigate whether these MEs could be used as drug delivery vehicles for prolonged release through in-

32 itation of drugs and polymers, are promising drug delivery vehicles for treating diseases with improv

33 of lipid bilayers have been investigated as drug-delivery vehicles for almost 20 years.

34 related apoptosis-inducing ligand (TRAIL) as drug-delivery vehicles for targeting and eradicating GBM

35 ions in developing cost-effective controlled drug delivery vehicles from renewable resources, with a

36 The magneto-plasmonic JVs were used as drug delivery vehicles, from which the release of a payl

37 The use of exosomes as a drug delivery vehicle has gained considerable interest.

38 use of nanoporous silica-based materials as drug-delivery vehicles has recently proven successful, y

39 Nanoscale drug delivery vehicles have been harnessed extensively a

40 To address this issue, stents coated with drug-delivery vehicles have been developed to deliver an

41 Drug-delivery vehicles have great potential to improve t

42 exosomes limits their use as an anti-cancer drug delivery vehicle; however, when delivered intratumo

43 icancer drug doxorubicin (DOX) are efficient drug delivery vehicles in cancer therapy using pH-respon

44 hat have attracted considerable attention as drug delivery vehicles in the past few years.

45 A light-activated hypoxia-responsive drug-delivery vehicle is described by Q.-D. Shen, Z. Gu,

46 sought to design a family of HP-beta-CD pro-drug delivery vehicles, known as polyrotaxanes (PR), cap

47 d to enhance product formulations, including drug delivery vehicles, medical imaging contrast agents,

48 hallenging due to the harsh environments any drug- delivery vehicle must experience before it release

49 Harnessing exosomes as therapeutic drug delivery vehicles requires a better understanding o

50 Fabrication of stimuli-triggered drug delivery vehicle s is an important milestone in tre

51 can be achieved with appropriately designed drug delivery vehicles such as nanoparticles, adult stem

52 Inflammatory components of the drug delivery vehicle, T cell responses, T and B cell ep

53 ent of pH-responsive nanoparticle-based dual drug delivery vehicles that are potentially capable of b

54 barriers requires the use of multifunctional drug delivery vehicles that can overcome a wide range of

55 the potential use of these macromolecules as drug delivery vehicles, the poorly water-soluble antican

56 ive distribution of solutes such as drugs or drug delivery vehicles through the vitreous humor.

57 otechnologies ranging from imaging probes to drug delivery vehicles to regenerative medicine, inexpen

58 fect an array of applications from design of drug delivery vehicles to tissue engineering systems.

59 imprints also have applications as selective drug delivery vehicles to tumours with the potential to

60 The BOSP also was used as a drug-delivery vehicle to treat corneal ulcers successful

61 for a variety of applications, ranging from drug-delivery vehicles to molecular sensors.

62 herwise functionalized polymeric particulate drug delivery vehicles, typical biocompatible particles

63 ial of a cyclodextrin-based nanocarrier as a drug delivery vehicle, using cell monolayers in vitro in

64 to the design of more effective nucleic acid drug delivery vehicles which take advantage of crotamine

65 ied the synthesis of antibody-functionalized drug delivery vehicles, which were benchmarked against a

66 iction of mucosal passage, and the design of drug delivery vehicles with tunable transport properties